BRANFORD, Conn., July 19,
2023 /PRNewswire/ -- Azitra, Inc. (NYSE American:
AZTR), a clinical-stage biopharmaceutical company focused on
developing innovative therapies for precision dermatology, today
announced the addition of two members to its board of directors,
Barbara Ryan and John Schroer.
"We are thrilled to further strengthen the Azitra team by
welcoming Barbara and John to our board and by leveraging their
wealth of knowledge in biotech, corporate strategy, and capital
markets," said Francisco Salva,
President and CEO of Azitra. "Both Barbara and John are widely
recognized leaders in biotech, and their additions to Azitra's
board will be invaluable as we grow the company to support clinical
trials and our partnership with Bayer."
Barbara Ryan is a Board Member of
Indivior PLC and MiNK Therapeutics, the CEO of Barbara Ryan
Advisors, and a Senior Advisor at Ernst & Young. Previously,
Ms. Ryan was a Wall Street research analyst, a Managing Director,
and Head of Pharmaceutical Research at Deutsche Bank. She began her
career covering the pharmaceutical industry at Bear Stearns. She
has been the lead analyst on high-profile transactions and has
raised over $1.5 billion for emerging
biopharma companies in IPOs, follow-ons, PIPEs, and convertible
debt transactions. She has led the IR/PR programs, or served as
senior strategic investor relations counsel, to firms including
Shire, Cardinal Health, Zoetis, Allergan, and Perrigo Agenus,
Radius Health, Rafael Holdings, Centrexion, Esperion, ContraFect,
Relypsa, Syndax, Barbara is a member of the Editorial Advisory
Board of Pharmaceutical Executive magazine where she authors a
monthly finance column and is a faculty member at the GLG
Institute.
John Schroer is the chief
financial officer at Alumis, where he started in March 2022. Previously, he was chief financial
officer at ArsenalBio from February
2021 to February 2022. Prior
to that role, Mr. Schroer served as chief financial officer and
treasurer at Translate Bio. From January
2014 to April 2018, Mr.
Schroer served as a director and sector head – healthcare at
Allianz Global Investors, a global asset management company. From
2009 to December 2013, he served as
president and chief investment officer at Schroer Capital, LP, a
financial services company that he founded. Mr. Schroer received a
B.S. in history and international relations and an MBA from the
University of Wisconsin-Madison.
"Azitra is an innovative company that is bringing much-needed
novel therapies to patients suffering from severe skin diseases,
which often has few or no therapeutic options," said Ms. Ryan. "I
am delighted to join Azitra's board and look forward to working
closely with the team on strategies to successfully grow the
company and deliver value to both patients and shareholders."
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision
dermatology using engineered proteins and topical live
biotherapeutic products. The Company has built a proprietary
platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented
by an artificial intelligence and machine learning technology that
analyzes, predicts and helps screen the Company's library of
strains for drug like molecules. The Company's initial focus is on
the development of genetically engineered strains of Staphylococcus
epidermidis, or S. epidermidis, which the Company considers to be
an optimal therapeutic candidate species for engineering of
dermatologic therapies. For more information, please visit
https://azitrainc.com/.
Forward Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on the Company's
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the final prospectus dated
June 15, 2023 relating to our initial
public offering filed with the SEC on June
21, 2023. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no duty to update such information except as required under
applicable law.
CONTACT
Norman
Staskey
staskey@azitrainc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azitra-adds-biotech-leaders-barbara-ryan-and-john-schroer-to-its-board-of-directors-301881189.html
SOURCE Azitra, Inc.